For the Inventor, By the Inventor

Enter assignee name

Mountain View, CA, United States of America

Bioelectron Technology Corporation

USPTO Granted Patents = 13

CIPO Patents = 20

EPO Patents = 11

Forward Citations = 27

Loading Chart...

Loading Chart...

30 inventors (with patents filed for the assignee):

Andrew W Hinman (5 out of 22 patents)

Paul Mollard (5 out of 26 patents)

Kieron E Wesson (4 out of 26 patents)

4. Guy M Miller (4 out of 22 patents)

5. William Dvorak Shrader (4 out of 22 patents)

6. Orion D Jankowski (3 out of 20 patents)

7. Viktoria Kheifets (2 out of 15 patents)

8. Christopher R Cornell (2 out of 4 patents)

9. Dana Davis (2 out of 4 patents)

10. Peter Giannousis (1 out of 7 patents)

11. Shazad Suchit (1 out of 4 patents)

12. Mahmoud Mirmehrabi (1 out of 15 patents)

13. Sidney M Hecht (1 out of 53 patents)

14. Kieron W Wesson (1 out of 1 patent)

13 patents: Sort by Forward Citations

1. 10251847 - Polymorphic and amorphous forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide (2019-04-09),

2. 10202325 - Methods for selective oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols (2019-02-12),

3. 10195161 - Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones (2019-02-05),

4. 10189830 - Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders (2019-01-29),

5. 10167251 - 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases (2019-01-01),

6. 10105325 - Treatment of pervasive developmental disorders with redox-active therapeutics (2018-10-23),

7. 10071978 - Process for the production of alpha-tocotrienol and derivatives (2018-09-11),

8. 10039722 - Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells (2018-08-07),

9. 10029971 - Methods for selective oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols (2018-07-24),

10. 9932286 - Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers (2018-04-03),

11. 9868711 - Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders (2018-01-16),

12. 9670170 - Resorufin derivatives for treatment of oxidative stress disorders (2017-06-06),

13. 9629815 - Benzoquinone derivatives for treating oxidative stress disorders (2017-04-25),

Bioelectron Technology Corporation is a leading biotech company specializing in the development of innovative medical devices and therapies. With a focus on bioelectronic technologies, we strive to improve the lives of patients worldwide. Our team of experienced scientists, engineers, and medical professionals work tirelessly to research, design, and manufacture cutting-edge solutions in the fields of neurology, cardiology, and rehabilitation. We are dedicated to pushing the boundaries of biomedical engineering to provide safe, effective, and life-changing solutions for various medical conditions.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 2 2025

13 Patents

#181 in Mountain View, CA

#5,472 in California

#23,092 in US

#43,586 in the World

Mountain View, CA, United States of America

Bioelectron Technology Corporation

Forward Citations = 27

30 inventors:

Andrew W Hinman (5 out of 22 patents)

Paul Mollard (5 out of 26 patents)

Kieron E Wesson (4 out of 26 patents)

4. Guy M Miller (4 out of 22 patents)

5. William Dvorak Shrader (4 out of 22 patents)

Please report any incorrect information to support@idiyas.com

Loading…